ANDA 90479, held by Watson Labs. Ethinyl Estradiol; Norgestimate, Norgestimate; Ethinyl Estradiol.
As of Nov 16, 2026, ANDA 90479 (Norgestimate And Ethinyl Estradiol, Norgestimate; Ethinyl Estradiol), held by Watson Labs, was first approved by FDA on Mar 9, 2011, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 9, 2011 | Original application | Approved | None posted |
| Norgestimate And Ethinyl Estradiol0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG · tablet;oral-28 | Ethinyl Estradiol; Norgestimate | Discontinued |
| Norgestimate; Ethinyl Estradiol0.215MG; 0.025MG · tablet; oral | Norgestimate; Ethinyl Estradiol | Rx |
| Norgestimate; Ethinyl Estradiol0.25MG; 0.025MG · tablet; oral | Norgestimate; Ethinyl Estradiol | Rx |
| Apr 29, 2022 | Supplement 2Labeling · Standard review | Approved | None posted |
| Feb 3, 2022 | Supplement 1Labeling · Standard review | Approved | None posted |
| Mar 9, 2011 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters